For a century, insulin has been the only drug available to type 1 diabetics. Now a raft of novel drugs are coming through the pipeline. Michael Eisenstein reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Source: ViaCyte
References
Fischer, B. et al. Expert Opin. Biol. Ther. 2, 265–272 (2010).
Couri, C.E. et al. J. Am. Med. Assoc. 301, 1573–1579 (2009).
Tang, Q. et al. J. Exp. Med. 199, 1455–1465 (2004).
Suarez-Pinzon, W.L. et al. Cell Transplant. 17, 631–640 (2008).
Thorel, F. et al. Nature 464, 1149–1154 (2010).
Skyler, J.S. et al. Diabetes Care 28, 1068–1076 (2005).
Malecki, M. & Klusacek, M. Biosimilars: ESAs, Insulins, and Human Growth Hormones (Decision Resources, 2009). <http://decisionresources.com/Products-and-Services/Report?r=drrppl0309>
El-Khatib, F.H. et al. Sci. Transl. Med. 2, 27ra27 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. More than insulin. Nat Biotechnol 29, 782–785 (2011). https://doi.org/10.1038/nbt.1967
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1967
This article is cited by
-
Toll-like receptor blocker slows beta cell death in type 1 diabetes
Nature Biotechnology (2012)
